Gilead Sciences, Inc.
333 Lakeside Drive
Foster City
California
94404
United States
Tel: 800-GILEAD-5 or 650-574-3000
Fax: 650-522-5800
Website: http://www.gilead.com/
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
YEAR FOUNDED:
1987
LEADERSHIP:
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
CLINICAL TRIAL:
Please click here for clinical trial information.
1311 articles with Gilead Sciences, Inc.
-
These stocks have been given a Strong Buy or Buy rating by 80% or more brokers.
-
Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma
1/18/2018
Kite announced it has entered into a clinical trial collaboration with Pfizer Inc. to evaluate the safety and efficacy of the investigational combination of Yescarta (axicabtagene ciloleucel) and Pfizer's utomilumab, a fully humanized 4-1BB agonist monoclonal antibody, in patients with refractory large B-cell lymphoma.
-
Watch Out: Gilead is Not Done Shopping
1/10/2018
Investors and analysts, after all, had been speculating, even nagging, on who the company should buy for several years. -
These prominent drug developers look to be enticing buys this month.
-
Cypralis and Gilead Agree on License Terms Under Which Cypralis Will Hold Exclusive Development and Commercialization Rights to Certain Jointly-Owned 'Cyprolides' for Acute and Chronic Degenerative Diseases
1/8/2018
Cypralis and Gilead Sciences have agreed that Cypralis will have exclusive development and commercialization rights to certain macrocyclic inhibitors of peptide bond isomerases, in all fields except for oncology and virology.
-
Why Investors Should Dodge Gilead in 2018
12/29/2017
Thanks to the Republican tax legislation, pharmaceutical stocks are set to continue their heady northward trajectory in 2018. -
It's no secret that the life sciences are increasingly international.
-
Gilead Could Acquire Galapagos Within Weeks
12/18/2017
Investors are salivating at the possibility of a hot merger-and-acquisition market in 2018. -
You don't have to be a dairy farmer to like a cash cow.
-
Galapagos assumes 35% of the co-promotion efforts in Germany, France, Italy, Spain, the United Kingdom, the Netherlands, Belgium, and Luxembourg.
-
Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors
12/15/2017
Gilead Sciences announced that Executive Chairman John Martin, PhD will transition from his current role of Executive Chairman to Chairman of the Board of Directors effective March 9, 2018.
-
Gilead Doubles Down on CAR-T
12/12/2017
Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its "Throttle" technology. -
The ZUMA-3 study results were presented in an oral session at the Annual Meeting of the ASH in Atlanta.
-
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
12/11/2017
With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission.
-
Gilead will pay an upfront payment of $175M, with additional milestone payments of up to $322M.
-
World's Top 10 Best Biotechs
12/7/2017
There are hundreds, even thousands of biotech and pharmaceutical companies. -
Gilead will partner with three coordinating centers to lead the corporate giving program of the initiative.
-
Gilead Launches Hepatitis C Treatment in China at 20% of U.S. Price
11/30/2017
Gilead priced its Sovaldi treatment for hepatitis C at $8,938 in China - about one-fifth the current price in the U.S.
-
X-Chem and Gilead Announce Drug Discovery Collaboration
11/28/2017
Agreement leverages X-Chem’s DEX DNA-Encoded Libraries and Gilead’s proprietary know-how to enable the discovery of new chemical entities.
-
CAR-T is a hot new area and there are companies hot on Gilead's tail, namely Juno, in a partnership with Celgene, and Novartis.